KOSDAQBiotech & Pharma278650

HLB bioStep

₩3,285▼ 5.74%2026-11-18 close
Market Cap
₩57.3B
Turnover
₩900M
Volume
260K
Shares out.
17.4M
PER
—
PBR
0.7×
EPS
-₩1,429
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

HLB bioStep: Shift to Alternative Testing, Profit Recovery Still Unproven

HLB bioStep is widening its business from animal-based non-clinical CRO work toward alternative testing methods (NAMs), but disclosed results show operating losses since 2023, so whether profits recover is the next thing to confirm.

  1. 1

    2025 revenue rose 27.3% year on year to KRW 74.1 billion, yet the company still posted an operating loss of KRW 8.62 billion.

  2. 2

    Over the last four quarters (Q4 2025 to Q3 2026), the net loss attributable to controlling shareholders totaled KRW 20.6 billion, with four consecutive quarters in the red.

  3. 3

    Revenue rests on two pillars, animal-facility construction (bio-infrastructure) and non-clinical CRO, which accounted for 51.15% and 28.24% respectively in the 2024 annual report.

  4. 4

    Phase-out moves on animal testing are read as a catalyst for alternative-test demand, and the company is responding through partnerships in organoids, AI and organ-on-a-chip.

  5. 5

    The debt ratio fell from 142.4% in 2022 to 54.1% in 2025, and operating cash flow turned positive again in 2025.

02

Business structure

HLB bioStep is a non-clinical contract research organization founded in 2012 and listed on KOSDAQ in November 2019. Its business rests on two pillars: bio-infrastructure, which designs, builds and maintains animal laboratories, and non-clinical CRO work, which evaluates the efficacy and toxicity of drug candidates.

In the 2024 annual report, animal-facility construction accounted for 51.15% of revenue and animal-based non-clinical CRO for 28.24%.

In CRO work the company mainly provides efficacy evaluation, a pharmacology-type test, and its chief executive has said it holds the leading share in that field; that figure is the CEO's own statement.

The company estimates the domestic non-clinical CRO market at KRW 300 billion to KRW 400 billion, with toxicity testing the largest outsourced segment.

Its customers include large domestic pharmaceutical companies, universities, public agencies, hospitals and biotech firms, and its construction arm ranked first among peers in the 2024 mechanical and gas construction capability rankings.

The company has a bioanalysis center, animal testing facilities and medical education infrastructure. In 2025 it obtained a general construction license, allowing it to build labs for animal-alternative testing.

At the March 2026 shareholder meeting, shareholders approved adding business purposes including medical devices, cell culture equipment and media, advanced biopharmaceuticals, AI and big-data products, and cosmetics. Management describes intense low-price bidding competition among a crowded group of CRO providers.

Unlike Samsung Biologics or Celltrion, which center on manufacturing (CDMO and biosimilars), HLB bioStep depends on outside demand for early-stage drug testing.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩24B₩500M1.9%
2025Q4₩18.7B-₩2.2B−11.8%
2026Q1₩13.5B-₩2.6B−19.4%
2026Q2₩16B-₩1.9B−11.9%
2026Q3₩14.7B-₩2.3B−15.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩86.3B₩6.4B-₩3B7.4%−4.4%142.4%
2023₩52.8B-₩1.3B-₩200M−2.4%−0.2%65.8%
2024₩58.2B-₩13B-₩8.6B−22.3%−7.7%44.1%
2025₩74.1B-₩8.6B-₩19B−11.6%−19.7%54.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed basis, annual revenue fell 38.8% from KRW 86.3 billion in 2022 to KRW 52.8 billion in 2023, then rose 10.1% to KRW 58.2 billion in 2024 and 27.3% to KRW 74.1 billion in 2025, increasing two years in a row from 2024 through 2025. 2022 was the largest year in the 2022 to 2025 period.

Operating profit of KRW 6.41 billion in 2022 turned into an operating loss of KRW 1.28 billion in 2023, widened to an operating loss of KRW 13 billion in 2024, and narrowed to an operating loss of KRW 8.62 billion in 2025. The operating margin moved from 7.4% in 2022 to -2.4% in 2023, -22.3% in 2024 and -11.6% in 2025.

Net loss attributable to controlling shareholders was KRW 3 billion in 2022, KRW 164 million in 2023, KRW 8.56 billion in 2024 and KRW 19 billion in 2025, a loss in each of the four years from 2022 to 2025. Net loss including non-controlling interests was KRW 20.3 billion in 2025.

The company attributed the 2025 change to a recovery in CRO revenue and higher infrastructure revenue, along with lower operating costs from reduced depreciation and energy expenses.

Operating cash flow went from KRW 6.48 billion in 2022 and KRW 5.19 billion in 2023 to -KRW 11.7 billion in 2024, then returned to KRW 3.09 billion in 2025.

At the end of 2025, total equity was KRW 100.9 billion, of which KRW 96.3 billion belonged to controlling shareholders, and total liabilities were KRW 54.6 billion.

By quarter, revenue went from KRW 24 billion in Q3 2025 to KRW 18.7 billion in Q4 2025 and KRW 13.5 billion in Q1 2026, then KRW 16 billion in Q2 2026 and KRW 14.7 billion in Q3 2026, down 38.8% year on year.

Operating profit of KRW 455 million in Q3 2025 became an operating loss of KRW 2.22 billion in Q4 2025, and the company has posted losses in four consecutive quarters through Q3 2026.

The Q4 2025 net loss attributable to controlling shareholders of KRW 14.1 billion was far larger than that quarter's operating loss, which points to a large contribution from non-operating items.

05

Industry analysis

As the US Food and Drug Administration announced a phase-out of animal testing, efforts to reduce reliance on animal studies in drug development are spreading across the industry. Regulators and pharmaceutical companies alike are expanding their use of NAMs, or alternative testing methods.

Some in the industry expect the government to lead the build-out of alternative-testing infrastructure, although timing and scale depend on how policy is carried out. The company estimates the market at KRW 300 billion to KRW 400 billion, with toxicity testing the largest outsourced segment.

Competition is fragmented, and company officials have said that many non-clinical CRO providers have led to fierce low-price bidding. The CEO has noted that regulatory submissions include one efficacy item but 15 toxicity items, which creates wide differences in pricing across test categories.

On technology, the company works with Nexel and Cellatrin on organoids, Basgen Bio on AI and Chiron on organ-on-a-chip. In Japan it has partnered with CMIC and Avitera to link demand for primate GLP toxicity studies and non-rodent efficacy testing.

Alternative-testing technology is still early, and how quickly the company can commercialize it appears to be a key variable for its competitiveness.

06

Outlook

The next periodic report will be the 2026 annual report. In August 2026 the company signed a memorandum of understanding with Japan's CMIC and Avitera to support domestic drugmakers' overseas primate GLP toxicity studies and to attract Japanese non-clinical demand.

In September 2026 it signed an MOU with the organoid firm Nexel on organoid-based alternative testing and non-clinical business, with joint sales and marketing to find new customers. The company is moving its NAMs technology into customer services centered on its own alternative testing center.

It also plans to turn accumulated study data into standard reference data and expand into a data platform business. In AI, it is developing a service that combines in silico prediction with NAMs validation together with Basgen Bio.

At the March 2026 shareholder meeting, a business-purpose expansion and a share consolidation were approved, and the company stated the consolidation aims to stabilize the share price and raise corporate value by keeping an appropriate number of tradable shares.

In a 2025 interview, the company set a 2025 breakeven target, but the disclosed 2025 operating loss of KRW 8.62 billion means that target was not met on a disclosed basis.

For 2026 results, the points to watch are whether non-clinical CRO orders recover and how utilization holds up in the bioanalysis and drug development services. Management of convertible bonds is also cited as a key variable.

07

Valuation

PER
—
PBR
0.7×
ROE
-20.7%
EPS
-₩1,429
BPS
₩5,249
Dividend per share
₩0

Because net losses have continued over the last four quarters, the price-to-earnings ratio cannot be calculated. On a disclosed basis, the company has been loss-making in every year from 2022 to 2025, so no PER has been computed for those years.

The price-to-book band has fallen sharply from its 2022 peak, and the stock currently trades below one times book value. Trading below the value of controlling shareholders' equity reads as a discount to net assets.

Because net assets shrink while losses continue, the size of that discount should be read alongside the trend in total equity. Dividend yield is close to nil, which places it below the industry average.

The factors that will shape the valuation picture are how quickly operating losses narrow and how fast quarterly revenue recovers.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Growing demand for alternative testing

The company is responding early to the US FDA's announced phase-out of animal testing. Some expect government-led build-out of alternative-testing infrastructure.

Its 2025 general construction license supports lab construction for alternative methods, and partnerships with organoid and AI firms are widening its evaluation services.

Standing in the infrastructure business

The bio-infrastructure business was reported as ranking first among its peers in the 2024 mechanical and gas construction capability rankings. It has long handled lab construction and upkeep for large drugmakers, universities and public agencies.

A business-purpose expansion approved at the March 2026 shareholder meeting gives it a basis for widening its scope.

Improving balance sheet and cash flow

The debt ratio fell from 142.4% in 2022 to 54.1% in 2025. Operating cash flow moved from -KRW 11.7 billion in 2024 to KRW 3.09 billion in 2025. Annual revenue rose in both 2024 and 2025, and the 2025 operating loss narrowed from 2024.

09

Bear factors

Prolonged losses

Operating losses have run for three consecutive years from 2023 to 2025. On net income attributable to controlling shareholders, the company has posted losses for four years running from 2022 to 2025. The 2025 net loss attributable to controlling shareholders widened to KRW 19 billion from KRW 8.56 billion in 2024. The last four quarters total KRW 20.6 billion in net losses attributable to controlling shareholders.

Uncertain order and revenue recovery

Q3 2026 revenue was KRW 14.7 billion, down 38.8% from a year earlier. Revenue rose in Q2 2026 from the prior quarter but fell again in Q3, so the recovery has been uneven. Non-clinical CRO results depend on pharma and biotech clients' R&D budgets, test orders and facility utilization, which adds to the volatility.

Funding and convertible bond risk

Order recovery and convertible bond management have been cited as key variables. Operating cash flow was negative in 2024, which makes funding conditions important alongside earnings. The breakeven target presented in a 2025 interview was not met on a disclosed basis.

10

Risk factors

Policy and regulatory risk

The pace and scope of the animal-testing phase-out remain uncertain. Whether government-led alternative-lab projects take off depends on policy timelines. If policy is delayed, the payback period for the construction license and alternative-testing services could also lengthen.

Financial and funding risk

With operating losses continuing, management of convertible bonds has been cited as a funding-side variable. Operating cash flow was negative in 2024 and turned positive in 2025, but quarterly results swing widely.

The Q4 2025 net loss attributable to controlling shareholders of KRW 14.1 billion far exceeded the operating loss of KRW 2.22 billion, so non-operating factors also deserve attention.

Concentration and pricing risk

Order timing depends on clients' R&D budgets and trial schedules, so it can shift from quarter to quarter. If low-price bidding persists, the pace of margin recovery could slow. Organoid and AI-based testing are at an early stage, so their revenue contribution is still small.

11

What to watch next

  1. Around late March 2027

    Filing of the 2026 annual report. This is when Q4 2026 results, full-year operating profit or loss, and the revenue share of alternative testing are first consolidated.

  2. Expected at the March 2027 annual shareholder meeting

    Whether the business purposes added in 2026 lead to actual operations, along with approval of the financial statements.

  3. Around May 2027, Q1 2027 quarterly report

    Whether quarterly revenue recovers from the KRW 14.7 billion in Q3 2026 and whether the operating loss narrows from the KRW 2.28 billion level.

  4. Ad hoc disclosures, when issued or converted

    Convertible bond disclosures covering issue size, conversion terms and use of proceeds.

  5. Ad hoc, when government tenders are announced

    Government alternative-lab tenders, and whether the company discloses related orders and their size.

12

Overall view

HLB bioStep is widening its model from animal-based non-clinical CRO toward an integrated evaluation system that combines alternative-testing technology.

Its disclosed results show operating losses since 2023, and four consecutive quarterly losses through Q3 2026, with a net loss attributable to controlling shareholders of KRW 20.6 billion over the last four quarters. Some recovery signs appeared in 2025, when revenue rose 27.3% and operating cash flow turned positive.

However, Q3 2026 revenue fell 38.8% year on year, so an order recovery has not yet shown up in results. Positive factors include demand from the animal-testing phase-out, the construction license and lab-building capability, and a lower debt ratio.

Negative factors include long-running losses, volatile quarterly revenue and funding-side variables such as convertible bond management. The price-to-book ratio is below one times, which means the market values the company low relative to net assets, though net assets are shrinking as losses continue.

The 2026 annual report is the next filing that will show the direction of full-year operating results and the revenue share of alternative testing.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. goinsider.kr
  2. job-post.co.kr
  3. news.nate.com
  4. job-post.co.kr
  5. investing.com
  6. job-post.co.kr
  7. comp.fnguide.com
  8. job-post.co.kr
  9. m.news.nate.com
  10. etoday.co.kr
  11. digitaltoday.co.kr
  12. pharm.edaily.co.kr
  13. supple.kr
  14. m.news.nate.com
  15. m.news.nate.com
  16. news.nate.com
  17. pharm.edaily.co.kr
  18. news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis